“Prospective Real-Life Multicenter Study of Tildrakizumab 200 mg for Moderate-to-Severe Psoriasis: Who Is the Ideal Patient?” (2024) Dermatology Practical & Conceptual, 14(4), p. e2024284. doi:10.5826/dpc.1404a284.